Pharmacological Management of Treatment-Resistant Obsessive-Compulsive Disorder

Abudy, Anat; Juven-Wetzler, Alzbeta; Zohar, Joseph
July 2011
CNS Drugs;2011, Vol. 25 Issue 7, p585
Academic Journal
Once considered rare and resistant to treatment, obsessive-compulsive disorder (OCD) has now emerged as a common, yet often unrecognized, psychiatric condition. Treatment with selective serotonin reuptake inhibitors (SSRIs) is effective in 40-60% of patients with OCD. Management of the remaining 40-60% of patients with treatment-resistant OCD is challenging. We review up-to-date evidence focusing on strategies for treatmentresistant OCD, including increasing the dose of SSRI, switching to another SSRI, augmentation with antipsychotics, and the use of serotonin noradrenaline (norepinephrine) reuptake inhibitors (SNRIs) and monoamine oxidase inhibitors (MAOIs). Finally, we provide a flow chart, which includes nonpharmacological interventions such as cognitive-behavioural therapy, family interventions and physical interventions such as neurosurgery and deep brain stimulation, alongside the pharmacological strategies.


Related Articles

  • Antidepressant Dosing for the Acute Treatment of Unipolar Depression. Solvason, Hugh Brent; DeBattista, Charles // Primary Psychiatry;Oct2009, Vol. 16 Issue 10, p30 

    Antidepressants are among the most commonly prescribed medications: The treatment of major depressive disorder can be challenging even in those without comorbid medical or psychiatric illness. The majority of people treated for a major depressive episode do not achieve complete remission after...

  • The Role of Serotonin Reuptake Inhibitors in the Treatment of Psychiatric Illness: An Update. Diaz, David R.; Poor, Maria C. // Annals of the American Psychotherapy Association;Fall2009, Vol. 12 Issue 3, p45 

    The article offers an update on the uses of selective serotonin reuptake inhibitors (SSRIs) in the treatment of psychiatric disorders. Since their introduction in 1987, SSRIs have replaced monoamine oxidase inhibitors and tricyclic antidepressants because of their easier titration and favorable...

  • Serotonin Reuptake Inhibitors: The Corner Stone in Treatment of Depression for Half a Century - A Medicinal Chemistry Survey. Moltzen, Ejner K.; Bang-Andersen, Benny // Current Topics in Medicinal Chemistry;Sep2006, Vol. 6 Issue 17, p1801 

    Inhibition of serotonin (5-HT) reuptake has been a central theme in the therapy of depression for half a century. Through the years these therapies have improved, particularly with regard to side effects, and today's selective serotonin reuptake inhibitors (SSRIs) constitute a reasonably...

  • Atypical Depression A Comprehensive Review. Chi-Un Pae; Tharwani, Haresh; Marks, David M.; Masand, Prakash S.; Patkar, Ashwin A. // CNS Drugs;2009, Vol. 23 Issue 12, p1023 

    Despite several decades of research, the characteristics distinguishing atypical depression from other depressive subtypes remain ambiguous. Multiple lines of evidence support the designation of atypical depression as a scientifically and clinically relevant subtype, including differences in...

  • Novel Monoamine Reuptake Inhibitors with 5-HT[sub 1A] Agonism Show Equivalent Weight Loss to Sibutramine but with a Superior Cardiovascular Profile in Rats. Thomas, Gerard H.; Babbs, Adam J.; McCormack, James G.; Widdowson, Peter S. // Diabetes;Jun2007 Supplement 1, Vol. 56, pA461 

    Sibutramine (Meridiaâ„¢) is a serotonin (5-HT)/norepinephrine (NE) reuptake inhibitor approved for the long-term treatment of obesity. Its use is associated with elevations in blood pressure (BP) and heart rate (HR) in some patients, limiting its use as well as the ability to dose titrate...

  • Obsessive-Compulsive Disorder: Over and Over. Sansone, Randy A.; Sansone, Lori A.; Currier, Glenn W. // Primary Care Reports;Sep2010, Vol. 16 Issue 9, p93 

    • Obsessive-compulsive disorder has become an increasingly apparent challenge in the community, and it may be difficult for primary care physicians to reliably identify these patients and provide effective treatment. • Patients with OCD rarely disclose their symptoms on their initial...

  • Catecholaminergic Strategies for the Treatment of Major Depression. Tremblay, Philippe; Blier, Pierre // Current Drug Targets;Feb2006, Vol. 7 Issue 2, p149 

    Although the selective serotonin reuptake inhibitors have become the first line medications for the treatment of depression, drugs primarily targeting the norepinephrine (NE) and/or the dopamine catecholaminergic systems are also effective. These include selective NE reuptake inhibitors, such as...

  • An Evaluation of the Cardiovascular Safety Profile of Duloxetine. Wernicke, Joachim; Lledó, Alberto; Raskin, Joel; Kajdasz, Daniel K.; Fujun Wang // Drug Safety;2007, Vol. 30 Issue 5, p437 

    Background and objective: In recent years, new classes of medication, such as the serotonin-noradrenaline reuptake inhibitors (SNRIs), have been developed for use in the treatment of major depressive disorder (MDD). For many years, treatment options were largely limited to the use of monoamine...

  • Obsessive-Compulsive Disorder: Diagnosis and Management. FENSKE, JILL N.; SCHWENK, THOMAS L. // American Family Physician;8/1/2009, Vol. 80 Issue 3, p239 

    Obsessive-compulsive disorder is an illness that can cause marked distress and disability. It often goes unrecognized and is undertreated. Primary care physicians should be familiar with the various ways obsessive-compulsive disorder can present and should be able to recognize clues to the...


Read the Article


Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics